Mymetics Corp (MYMX)

[Phosphene]

Keytruda-Merck-IO Biotech

3-23-20

Merck knows for sure.

Better Responses with IO102-Keytruda Combo Likely in Ongoing NSCLC Trial

https://immuno-oncologynews.com/2020/03/23/io102-keytruda-combo-likely-meet-response-goal-phase-2-trial-metastatic-nsclc/

5-25-20

https://www.mymetics.com/media-center/exploratory-project-compare-io-biotech-antigens-linked-mymetics-virosomes-preclinical-tumor-model/